

CEE, CIS AND, BALTIC TARGETED MARKET ACCESS MONITORING

Certara's Tier 3 business partner decided to get an overview of selected brand situations in the Central & Eastern European (CEE) region, Commonwealth of Independent States (CIS), and Baltic countries. The project consisted of two parts: targeted retrospective search in Market Access Radar (MAR) repository and MAR targeted daily prospective monitoring of brand with monthly status updates.

We have searched: Information from CEE, CIS, and Baltic Ministries of Health and other relevant sources; reimbursement recommendations, not only CEE/CIS/Baltic, but also from other well-recognized agencies; information on changes in legal provisions regulating the financing of health technologies from public funds; news on technology safety, new marketing authorizations, variations in registered and reimbursed indications published by EMA, HMA, FDA, MHRA, European Commission and other national institutions and other valuable information which may impact reimbursement.



MORE THAN 10,000 DATABASE ENTRIES ARE SEARCHED

1 SELECT COUNTRY:

- | | |
|------------|----------------------|
| Latvia | Albania |
| Lithuania | Armenia |
| Macedonia | Azerbaijan |
| Moldova | Belarus |
| Montenegro | Bošnia & Herzegovina |
| Poland | Bulgaria |
| Romania | Croatia |
| Russia | Cyprus |
| Serbia | Czech Republic |
| Slovakia | Estonia |
| Slovenia | Georgia |
| Tajikistan | Greece |
| Turkey | Hungary |
| Ukraine | Kazakhstan |
| Uzbekistan | Kyrgyzstan |

2 SELECT INFORMATION:

- Drug
- Medical device
- Competitive technologies
- Disease/indication
- Public funds
- Change in legislation
- Health policy
- Approach to innovations and orphan
- Pricing changes
- Regulatory affairs
- OTHER

3 SELECT SOURCES:


- Media and sectoral press
- EMA, HMA, FDA, MHRA
- HTA Agencies
- Ministries of Health

4 ASK QUESTIONS:

- Is the TECHNOLOGY registered?
- Is the TECHNOLOGY reimbursed under 'normal conditions' (standard procedure)?
- Is the TECHNOLOGY reimbursed (available for patients) under any special condition, such as: individual access program, early access program, etc.?
- Is the TECHNOLOGY during/after the preparation of reimbursement application or during negotiation process?

TARGETED PROSPECTIVE MONITORING IN MAR REPOSITORY WITH LOCAL EXPERTS SUPPORT

COMThanks to customized MAR profiles, brand monitoring information was provided to the sponsor from the CEE region and beyond. Reports were delivered daily, with one monthly summary as an addition. The Ask the Expert functionality enabled the sponsor to get in touch with the MAR team along the way for additional expert advice.



CONTACT US TO LEARN MORE

CONTACT@MARKETACCESS-RADAR.COM